Dr. Weiss on Disease-Control Rate of Immunotherapy for Lung Cancer

Jared Weiss, MD
Published: Wednesday, Feb 01, 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

Durable disease control has been observed in a minority of patients due to immunotherapy, says Weiss. With the newer therapies of PD-1/PD-L1 both alone and in combination with CTLA-4 inhibitors and other agents, higher rates of disease control is being seen than previously.

Only a small number of patients achieve what appears to be a cure, but immunotherapy is a bigger step in the evolution of cancer care. Many people are thriving longer with lower toxicities but a cure still needs to be researched, explains Weiss.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

Durable disease control has been observed in a minority of patients due to immunotherapy, says Weiss. With the newer therapies of PD-1/PD-L1 both alone and in combination with CTLA-4 inhibitors and other agents, higher rates of disease control is being seen than previously.

Only a small number of patients achieve what appears to be a cure, but immunotherapy is a bigger step in the evolution of cancer care. Many people are thriving longer with lower toxicities but a cure still needs to be researched, explains Weiss.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x